BowTiedBiotech - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
BowTiedBiotech

BowTiedBiotech

Creator
0 followers

Pseudonymous biotech insider; provides daily biotech news, startup financing updates, and trend analysis.

Recent Posts

Deal Flow Quality Trumps Picking Skill for VC Success
Social•Jan 26, 2026

Deal Flow Quality Trumps Picking Skill for VC Success

Deal Flow Quality beats “picking skill” The figure below is a reminder that most VC chest-thumping is aimed at the wrong variable. In venture, outcomes are driven by two levers: >Pool quality (base rate): how many real winners exist in what you see >Picking skill (accuracy): how well you separate winners from noise When the pool is weak, even strong investors are forced into false positives. The signal is too thin. Better judgment helps, but it hits a ceiling fast. The chart makes the point visually: >A small improvement in pool quality drives a big jump in portfolio hit rate >Even a large improvement in picking skill moves the needle less Reason is simple Bayes. Pool quality sets the prior. Picking skill only works inside that constraint. You can’t select winners that aren’t in your universe. So “proprietary dealflow” is not a flex. It’s the job. Alpha is upstream of everything, better origination, better timing, better information flow. If you want higher hit rates, start with a better pool.

By BowTiedBiotech
Five 2026 Biotech Black Swans Threaten Industry Stability
Social•Jan 25, 2026

Five 2026 Biotech Black Swans Threaten Industry Stability

🧨 5 Potential Black Swan Biotech Events in 2026 Low probability. Massive impact. Worth thinking about. 😲Multiple deaths from incorrect AI health advice One high-profile event could trigger lawsuits, regulation, and an overnight sentiment flip on AI-in-healthcare. 😲Sudden safety, supply, or reimbursement shock...

By BowTiedBiotech
AI Could Slash Primary Care to $5 Copay
Social•Jan 25, 2026

AI Could Slash Primary Care to $5 Copay

Predictions for the future of AI - the one that catches my attn most is the $5 copay Today; You wake up with a sore throat and grab the first primary care slot you can find. Ten minutes with a rushed clinician...

By BowTiedBiotech
Biotech Shifts: New Masks, Diversification, AI‑Driven Trials
Social•Jan 23, 2026

Biotech Shifts: New Masks, Diversification, AI‑Driven Trials

A few key takeaways from this week’s top biotech news: $BMY & $JANX: Tackling T-cell toxicity with tumor-activated masks. $PFE & $NVAX: Diversifying beyond mRNA for strategic risk hedging. $JNJ: projecting >$100B revenue post-Stelara patent cliff. $RHHBY: Building manufacturing moats for obesity market dominance. FDA:...

By BowTiedBiotech
AI-Designed Drugs Double Phase‑I Success Rate
Social•Jan 23, 2026

AI-Designed Drugs Double Phase‑I Success Rate

Phase I AI-discovered molecules show an 80-90% success rate in Ph1-to-Ph2 transition. *vs historic benchmark ~50% https://t.co/rC03gNjOPo https://t.co/AcK2XxfrW0

By BowTiedBiotech
Progress in Cancer Fight, Yet GBM, Colorectal, Liver
Social•Jan 22, 2026

Progress in Cancer Fight, Yet GBM, Colorectal, Liver

Great progress update on the war on cancer “GBM, colorectal and liver still look very challenging...” See below for detail point down 👇🏼 https://t.co/UTFZSsDVcX

By BowTiedBiotech
CORT Shows 30% Pre‑market
Social•Jan 22, 2026

CORT Shows 30% Pre‑market

$CORT +30% pre-market Still room to run? >OS met: HR 0.65 (-35% death risk), mOS 16.0 vs 11.9 mo (+4.1) >PFS (prior): HR 0.70 (-30%) >n=381, safety ≈ control, no biomarker needed What’s next: full dataset at a med meeting; FDA PDUFA Jul 11, 2026...

By BowTiedBiotech
CRVS Shows Promising AD Efficacy, Needs Tissue Validation
Social•Jan 20, 2026

CRVS Shows Promising AD Efficacy, Needs Tissue Validation

$CRVS +57% premarket on AD Cohort-4: randomized PBO-controlled signal (EASI-75 75%, mean EASI −72% vs −40% PBO; p=0.035) with clean safety, real but fragile (n=12 vs 12; 10 PBO-evaluable). 📝No skin-biopsy disclosed. While exiting progress serum PD != tissue reversal....

By BowTiedBiotech
Biotech Success Now Hinges on De‑risking and Speed
Social•Jan 17, 2026

Biotech Success Now Hinges on De‑risking and Speed

We asked the biotwit some interesting industry questions. The answers were telling... 5 takeaways from last week’s biotech polls: 1️⃣ When efficacy ceilings are hit, risk wins. Safety, tolerability, and long-term risk profile now beat novelty and precision once drugs work “well enough.” 2️⃣...

By BowTiedBiotech
IBRX Surge Fueled by 700% Revenue Forecast, Not Anecdote
Social•Jan 17, 2026

IBRX Surge Fueled by 700% Revenue Forecast, Not Anecdote

$IBRX is trending on the TL - but the +40% pop more likely driven by prelim 2025 net product revenue of ~$113M, up ~700% y/y and not this tiny N CD19 CAR-NK + ritux anecdote in a rare lymphoma. https://t.co/64wkMTGX9v

By BowTiedBiotech
Mega‑Fund Returns Require Unrealistic Share of Biotech Exit Pie
Social•Jan 16, 2026

Mega‑Fund Returns Require Unrealistic Share of Biotech Exit Pie

The Mega-Fund Math vs Reality Below is a simple case study on fund math. People are asking if a16z can really do a 3-5x on a $15B fund. To 3x net on $15B, you need ~$45B back. Assume ~5% ownership at exit. 👉 That...

By BowTiedBiotech
Gene Therapy Leads Durable Clinical Value in Five Years
Social•Jan 16, 2026

Gene Therapy Leads Durable Clinical Value in Five Years

Which modality has the cleanest path to durable clinical value over the next 5 years?

By BowTiedBiotech
Acute Infections May Reopen Investment Door for Anti‑Infectives
Social•Jan 16, 2026

Acute Infections May Reopen Investment Door for Anti‑Infectives

1/ The Back Door Is Open How Acute Infection Could Make Anti-Infectives Investable Again Anti-infectives never died. The business model did. Low prices. Short courses. High resistance risk. Pharma walked. Now look at Alfasigma stepping into HSV encephalitis. Small deal. Narrow indication. Big implication....

By BowTiedBiotech
Genetically Informed ALS Therapies Extend Beyond Mutation‑Specific Targets
Social•Jan 14, 2026

Genetically Informed ALS Therapies Extend Beyond Mutation‑Specific Targets

Nice ALS market map 👇 When precision approaches go broad….looks like yes that can happen. “…a third category being overlooked: 28 programs that are genetically informed but not mutation-restricted. Examples: drugs targeting TDP-43 protein clumps or repeat RNA toxicity. These mechanisms...

By BowTiedBiotech
Milestone‑Heavy PD‑L1×VEGF Deals Signal Low Conviction
Social•Jan 13, 2026

Milestone‑Heavy PD‑L1×VEGF Deals Signal Low Conviction

PD(L1)xVEGF the Keytruda replacement? The deal making market is clearly not pricing it that way. 🗣️“We want exposure to a hot mechanism, but we want most of the price contingent on Phase 2/3 and commercial proof.” Great analysis below...

By BowTiedBiotech
AstraZeneca Launches First TROP2 NMR‑guided Phase 3 NSCLC Trial
Social•Jan 13, 2026

AstraZeneca Launches First TROP2 NMR‑guided Phase 3 NSCLC Trial

👀 Real precision medicine from $AZN $DSNKY TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer “…TROPION-Lung17 is the first phase 3 clinical trial to prospectively enroll patients with tumors...

By BowTiedBiotech
Eliminate Uncertainty to Boost Investor Confidence and XBI
Social•Jan 13, 2026

Eliminate Uncertainty to Boost Investor Confidence and XBI

Good dialog - worth the 3.5min listen 👂 TLDR - investors do not like uncertainty. Macro uncertainty, technical uncertainty, commercial uncertainty. Remove uncertainty and number go up $XBI

By BowTiedBiotech
Pharma Accelerates PD1‑VEGF Combo Trials Across Major Players
Social•Jan 12, 2026

Pharma Accelerates PD1‑VEGF Combo Trials Across Major Players

Expect BIG activity from pharma with PD1xVEGF combos… $SMMT Announces Clinical Trial Collaboration with $GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) $PFE has already telegraphed (and started to operationalize) the same playbook. https://t.co/JTY2cuJtMG https://t.co/0zCI8zFouB

By BowTiedBiotech
Checklist to Spot Viable Cytokine Bispecifics Amid Hype
Social•Jan 11, 2026

Checklist to Spot Viable Cytokine Bispecifics Amid Hype

The Next Generation of Multi-Functional I&I Therapeutics | Ep. 903 How to Pick Winners From a Crowded Cytokine War Bispecifics are everywhere, China biotech is running every combo possible including the ones you have not thought of yet. Trispecifics are next, and...

By BowTiedBiotech
Tissue‑resident Macrophages Drive Cardioprotection, Not Tolerance
Social•Jan 11, 2026

Tissue‑resident Macrophages Drive Cardioprotection, Not Tolerance

1/ 💡While much of the immunology field is fixated on immune reset in B cells and autoimmunity, a quieter version of the same idea is emerging in cardio-immunology. 🫀 Except we are not talking about lymphocytes. This is all about tissue-resident macrophages. And...

By BowTiedBiotech
Biotech Deal Surge: Wnt, NLRP3, GLP‑1, and More
Social•Jan 9, 2026

Biotech Deal Surge: Wnt, NLRP3, GLP‑1, and More

Your Weekly Biotech News Fix | Ep. 901 Designed to be consumed as a quick scroll 🧬 Parabilis - $305M Wnt bet 🔥 $LLY - Buys $VTYX (NLRP3) 🎯 $PFE - Cartography antigen deal 🧲 $AMGN - Dark Blue acquisition 🦠 $GSK / $IONS - HBV...

By BowTiedBiotech
ASND Combo Shows Robust Growth, Heads to Phase 3
Social•Jan 9, 2026

ASND Combo Shows Robust Growth, Heads to Phase 3

$ASND -2.5% Looks approvable (priority review; class precedent). Combo = upside optionality, not the label. COACH Wk-52 open-label Ph2 (n=21) CNP + hGH >AGV: 8.8 (naïve) / 8.42 cm/yr (prior-CNP), >97th pct vs avg-stature >Z-score: +1.02 / +0.86; proportionality/arm-span up; bone age “consistent” >AEs...

By BowTiedBiotech
UniQure Secures FDA Type A Meeting
Social•Jan 9, 2026

UniQure Secures FDA Type A Meeting

$QURE +13% uniQure Announces Type A Meeting Scheduled with FDA 🍿 uniQure Announces Type A Meeting Scheduled with FDA https://t.co/iqZkaNYD7Z https://t.co/lRcR6vgV0D

By BowTiedBiotech
Market Unconvinced: KYRS Needs Functional Data
Social•Jan 9, 2026

Market Unconvinced: KYRS Needs Functional Data

$KYRS +1% Nice science, market not convinced. KB407 shows delivery + CFTR protein in bronchoscopic biopsies, but no sweat chloride/NPD/FEV1. End of day, PD != clinical translation. Also a crowded CF GTx race = priced in. $FDMT 4D-710 (ppFEV1/LCI signals),...

By BowTiedBiotech
JPM Acts as Audit, Reveals Biotech Translation Friction
Social•Jan 9, 2026

JPM Acts as Audit, Reveals Biotech Translation Friction

JPM Isn’t a Conference. It’s an Audit. What 1,000 companies and 6 years of data quietly tell you about biotech translation. Part 1. Why you should care. JPM decides who looks fundable before a single new dataset drops. That sounds backward, but it...

By BowTiedBiotech
Investors Now Require Clean Data and Clear Milestones
Social•Jan 9, 2026

Investors Now Require Clean Data and Clear Milestones

From Proof to Payoff | Ep. 900 2025 changed biotech translation. Capital came back with rules. No data, no money. Clean data, financing opens. If your next readout doesn’t force a decision, you stall, no matter how pretty the biology looks. What the market pays for...

By BowTiedBiotech
Oral MRT‑8102 Shows Rapid Biomarker Drop, Upside Remains
Social•Jan 7, 2026

Oral MRT‑8102 Shows Rapid Biomarker Drop, Upside Remains

$GLUE +45% MRT-8102 delivers eye-catching 4-week biomarker win with clean early safety and the convenience of an oral approach. MRT-8102 degrades NEK7, a scaffolding protein essential for NLRP3 inflammasome assembly, shutting down upstream activation of IL-1β/IL-18 and downstream IL-6/hsCRP, which...

By BowTiedBiotech

Page 2 of 2

← Prev12